Jiangsu Vcare Unveils Phase I Clinical Trial Results of TRK Inhibitor VC004 at 2024 ASCO
Published Time:
2024-06-07 17:08
Source:
On June 2, 2024，Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) unveiled the Phase I clinical trial results of its self-developed next-generation TRK inhibitor, VC004, for the treatment of locally advanced/metastatic solid tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract ID: #3101
This study is a first-in-human, multicenter, single-arm, open-label Phase I/II clinical trial (ClinicalTrials.gov Identifier: NCT04614740). The Phase I portion is designed to evaluate the safety, efficacy, and pharmacokinetic (PK) profile of VC004 in patients with locally advanced/metastatic solid tumors.
Key Findings: During the Ib dose-expansion phase, 35 patients (median age: 57.0 years; 97% with ECOG score ≤1) treated with VC004 50 mg twice daily (recommended Phase II dose, RP2D) achieved unconfirmed and confirmed ORRs of 75.9%(95% CI: 56.5–89.7) and 69.0%(95% CI: 49.2–84.7), respectively, as assessed by RECIST v1.1 criteria.
In the subgroup of patients naive to TRK-TKI treatment, the unconfirmed and confirmed ORRs reached 80.8%(95% CI: 60.6–93.4) and 73.1%(95% CI: 52.2–88.4), respectively. Median DoR and PFS were not yet reached. Notably, 28.6% of TRK-TKI treatment-naive patients maintained responses for ≥12 months, and 75.8% achieved PFS ≥9 months. Among three patients who progressed after prior TRK-TKI therapy, two exhibited tumor shrinkage, including one partial response (PR; 39.6%). Of six patients with baseline brain metastases, two experienced intracranial lesion reductions of 61.8% and 25%, while non-target lesions achieved complete resolution in two others after four months of treatment.
Safety Profile, TRAEs were predominantly Grade 1–2, with no fatal TRAEs reported. Common TRAEs (≥20%) included dizziness, weight gain, hypertriglyceridemia, anemia, elevated alanine aminotransferase (ALT), elevated aspartate aminotransferase (AST), hypercholesterolemia, and hyperuricemia. No new safety signals were observed compared to other TRK inhibitors.
VC004 demonstrated dose-proportional exposure across doses of 25–200 mg and favorable oral bioavailability.
VC004 exhibited safety comparable to first-generation TRK-TKIs and robust efficacy against NTRK fusion-positive tumors. Significant clinical benefits were observed not only in TRK-TKI treatment-naive patients but also in those with TRK-TKI resistant disease or baseline brain metastases.
Note: All data are preliminary and subject to confirmation in ongoing trials.
Related News
31
2025
/
10
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Jiangsu Vcare) announced the completion of first patient enrollment in the Phase Ⅱ clinical trial of VC005 Tablets. This independently developed next-generation highly selective JAK1 inhibitor is being evaluated for the oral treatment of non-segmental vitiligo (NSV). The trial aims to assess the efficacy, safety, and PK profile of VC005 Tablets in Chinese adult NSV patients, providing a basis for the selection of dosage in subsequent clinical studies.
View Details
29
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) has achieved a major milestone in the Phase Ⅲ clinical trial of VC005 Tablets – the company's independently developed second-generation highly selective JAK1 inhibitor for oral treatment of moderate-to-severe atopic dermatitis (AD) – with the successful completion of full patients enrollment. This multicenter, randomized, double-blind, placebo-controlled pivotal Phase Ⅲ study aims to further validate the efficacy and safety of VC005 Tablets in adult patients with moderate-to-severe AD. The smooth completion of enrollment marks a crucial step forward for this innovative drug towards clinical application.
View Details
15
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) announced the official initiation of the Phase III clinical trial of VC005 Tablets—a self-developed second-generation highly selective JAK1 inhibitor—for the oral treatment of ankylosing spondylitis (AS). This marks the second Phase III clinical trial of VC005 Tablets, following the one for oral treatment of moderate-to-severe atopic dermatitis (AD), signifying that the AS indication has entered the confirmatory clinical research stage.
View Details
12
2025
/
09
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare) officially initiated the Phase II clinical trial of VC005 Tablets, a second-generation highly selective JAK1 inhibitor independently developed by the company, for a new oral indication – the treatment of non-segmental vitiligo (NSV).
View Details
11
2025
/
08
August 8, 2025 – Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced today that it has entered into an exclusive strategic partnership with Huadong Medicine (Hangzhou) Co., Ltd., a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (000963.SZ, "Huadong Medicine"), for the commercialization rights of Jiangsu Vcare’s innovative product VC005 tablets in mainland China.
View Details
31
2025
/
07
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the completion of full patient enrollment for its Phase II clinical trial of the self-developed, next-generation highly selective JAK1 inhibitor, VC005 topical gel, for the treatment of mild-to-moderate Atopic Dermatitis (AD). This marks a significant milestone in the VC005 gel development program.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn